Administering hydroxychloroquine to women with systemic lupus erythematosus (SLE) can reduce the risk of fetal heart block and anti-SSA/SSB-related cardiac complications in neonatal lupus (9). This evidence concerns the gene CALR and systemic lupus erythematosus.